Estimates are averaged percentages based on Scalp Cooling Registry data of over 7,000 real-world patients. Regimens and dosages included are those that have exceeded a minimum sample size threshold (n=10) to offer an interpretation of efficacy.
Depending on sample size, results may show greater variation. There are no guarantees, but an indication of potential outcome will help to manage expectations. Pre-infusion and post-infusion cooling times per regimen are also displayed.
Start
Select your regimen
Chemotherapy Regimen & Dosage >
Select your chemo type and dose >
Cabazitaxel (Jevtana) 25-50
Cabazitaxel (Jevtana) 35-55
Carboplatin 6 + Etoposide 50
Cisplatin 25-75
Cyclophosphamide 100 + Methotrexate 40 + 5-FU 600
Cyclophosphamide 600 + Methotrexate 40 + 5-FU 600
Docetaxel (Taxotere) 35
Docetaxel (Taxotere) 75
Docetaxel (Taxotere) 80
Docetaxel (Taxotere) 100
Docetaxel (Taxotere) 100H
Doxorubicin (Adriamycine) 25
Doxorubicin (Adriamycine) 60
Epirubicin 25-90
Epirubicin 50 + Oxaliplatin 130
Eribulin
Irinotecan (Campto) 180-250
Irinotecan (Campto) 260-340
Irinotecan (Campto) 350
Methotrexate 10-30
Mitomycin 60
Mitomycin 60 + Cyclophosphamide 600
Paclitaxel (Taxol) 50-75
Paclitaxel (Taxol) 80
Paclitaxel (Taxol) 80 + Trastuzumab
Paclitaxel (Taxol) 90
Paclitaxel (Taxol) 175
Pegylated liposomal Doxorubicin 30-50
Pegylated liposomal Doxorubicin + Carboplatin 5
Pemetrexed 500
Vinorelbine (Navelbine) 25
Vinorelbine (Navelbine) 30
AC: doxorubicin 60 + cyclophosphamide 600
AC-D: doxorubicin 60 + cyclophosphamide 600 followed by docetaxel 100
AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 80
AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 80 + Trastuzumab
AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 175
AC-T: doxorubicin 60 + cyclophosphamide 600 followed by paclitaxel 175 + Trastuzumab
If you can’t find your regimen on the list, this is because there isn’t enough data within the Registry to be able to give a useful answer. It may be worth asking your clinician if there is a similar regimen to the one you are receiving on the list that can give you an idea.
Please be aware that Herceptin and Perjeta (also known as trastuzumab and pertuzumab) are not chemotherapy drugs and therefore are not included in the list. For example, if you are receiving docetaxel, carboplatin, trastuzumab, and pertuzumab you should look for docetaxel and carboplatin. If you would like more information, please do get in touch.
Why does it show the chance of retaining 50% of my hair, not just a percentage of hair retention on its own?
This reflects the way the Registry data was collected. Retaining 50% or more of your hair is usually the clinical definition of scalp cooling success. The calculator shows the percentage chance of what would be considered a ‘successful’ outcome.
Scalp cooling is different for everybody
Each person’s experience and outcomes from cold capping are different. For some people, this can add more uncertainty to an already stressful and upsetting time. For others, there is a comfort in knowing they tried, and all hair retention is a bonus.
The scalp cooling process is much more complex than a potential percentage; the decision-making guide can give you an indication of likely hair retention. There is so much emotion tied up in cancer treatment and hair loss that the decision of whether scalp cooling is right for you is multi-dimensional.
Paxman Group is a global medical technology company focused on improving quality of life for people undergoing chemotherapy through innovative side-effect management solutions.
Translation of this website is facilitated by Google, therefore there may be discrepancies or inaccuracies in the language used
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
